Viracta Therapeutics, Inc.

NasdaqCM:VIRX Stock Report

Market Cap: US$9.9m

Viracta Therapeutics Past Earnings Performance

Past criteria checks 0/6

Viracta Therapeutics has been growing earnings at an average annual rate of 5.7%, while the Biotechs industry saw earnings growing at 22.1% annually.

Key information

5.7%

Earnings growth rate

77.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Viracta Therapeutics names Mark Rothera as new CEO

Sep 19

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

Sep 07

Viracta Therapeutics GAAP EPS of -$0.28

Aug 09

Viracta Therapeutics files for $200M mixed shelf offering

May 28

Revenue & Expenses Breakdown

How Viracta Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:VIRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-431433
30 Jun 240-451534
31 Mar 240-481736
31 Dec 230-511733
30 Sep 230-481831
30 Jun 230-532530
31 Mar 230-512528
31 Dec 220-492426
30 Sep 220-502327
30 Jun 220-471627
31 Mar 220-461626
31 Dec 210-1151524
30 Sep 210-1101420
30 Jun 210-991116
31 Mar 210-94814
31 Dec 200-19513
31 Dec 190-1439
31 Dec 181-1026

Quality Earnings: VIRX is currently unprofitable.

Growing Profit Margin: VIRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VIRX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.7% per year.

Accelerating Growth: Unable to compare VIRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: VIRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:24
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Viracta Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew BerensLeerink Partners LLC
Hartaj SinghOppenheimer & Co. Inc.